The role of hepatic microenvironment in hepatic fibrosis development

References

• Marcellin P, Kutala BK. Liver diseases: a major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018;38(Suppl 1):2–6.
   PubMedGoogle Scholar
• Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol. 2014;20(23):7312–7324.
   PubMed Web of Science ®Google Scholar
• Rockey DC, Bell PD, Hill JA. Fibrosis–a common pathway to organ injury and failure. N Engl J Med. 2015;372(12):1138–1149.
   PubMed Web of Science ®Google Scholar
• Ginès P, Krag A, Abraldes JG, et al. Liver cirrhosis. Lancet. 2021;398(10308):1359–1376.
   PubMed Web of Science ®Google Scholar
• Friedman SL, Sheppard D, Duffield JS, et al. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med. 2013;5(167):167sr1–167sr1. (
   PubMed Web of Science ®Google Scholar
• Rui L. Energy metabolism in the liver. Compr Physiol. 2014;4(1):177–197.
   PubMed Web of Science ®Google Scholar
• Henderson J, O’Reilly S. The emerging role of metabolism in fibrosis. Trends Endocrinol Metab. 2021;32(8):639–653.
   PubMed Web of Science ®Google Scholar
• Chang ML, Yang SS. Metabolic signature of hepatic fibrosis: from individual pathways to systems biology. Cells. 2019;8(11):1423.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang W, Cao Q, et al. Mitochondrial dysfunction in fibrotic diseases. Cell Death Discov. 2020;6:80.
   PubMed Web of Science ®Google Scholar
• Bahr MJ, Ockenga J, Böker KH, et al. Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance. Am J Physiol Endocrinol Metab. 2006;291(2):E199–E206.
   PubMed Web of Science ®Google Scholar
• Lee NCW, Carella MA, Papa S, et al. High expression of glycolytic genes in cirrhosis correlates with the risk of developing liver cancer. Front Cell Dev Biol. 2018;6:138.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Schmidberger H, Mayer A. The warburg effect: essential part of metabolic reprogramming and Central contributor to cancer progression. Int J Radiat Biol. 2019;95(7):912–919.
   PubMed Web of Science ®Google Scholar
• Li J, Wang T, Xia J, et al. Enzymatic and nonenzymatic protein acetylations control glycolysis process in liver diseases. Faseb J. 2019;33(11):11640–11654.
   PubMed Web of Science ®Google Scholar
• Lian N, Jin H, Zhang F, et al. Curcumin inhibits aerobic glycolysis in hepatic stellate cells associated with activation of adenosine monophosphate-activated protein kinase. IUBMB Life. 2016;68(7):589–596.
   PubMed Web of Science ®Google Scholar
• Chen Y, Choi SS, Michelotti GA, et al. Hedgehog controls hepatic stellate cell fate by regulating metabolism. Gastroenterology. 2012;143(5):1319–1329.e11.
   PubMed Web of Science ®Google Scholar
• Wang F, Jia Y, Li M, et al. Blockade of glycolysis-dependent contraction by oroxylin a via inhibition of lactate dehydrogenase-a in hepatic stellate cells. Cell Commun Signal. 2019;17(1):11.
   PubMedGoogle Scholar
• Nishikawa T, Bellance N, Damm A, et al. A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease. J Hepatol. 2014;60(6):1203–1211.
   PubMed Web of Science ®Google Scholar
• Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27:441–464.
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033.
   PubMed Web of Science ®Google Scholar
• Satyanarayana G, Turaga RC, Sharma M, et al. Pyruvate kinase M2 regulates fibrosis development and progression by controlling glycine auxotrophy in myofibroblasts. Theranostics. 2021;11(19):9331–9341.
   PubMed Web of Science ®Google Scholar
• McPhail MJW, Shawcross DL, Lewis MR, et al. Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis. J Hepatol. 2016;64(5):1058–1067.
   PubMed Web of Science ®Google Scholar
• Nie Y, Liu LX, Chen T, et al. Serum lactate level predicts 6-months mortality in patients with hepatitis B virus-related decompensated cirrhosis: a retrospective study. Epidemiol Infect. 2021;149:e26.
   PubMed Web of Science ®Google Scholar
• Kottmann RM, Trawick E, Judge JL, et al. Pharmacologic inhibition of lactate production prevents myofibroblast differentiation. Am J Physiol Lung Cell Mol Physiol. 2015;309(11):L1305–12.
   PubMed Web of Science ®Google Scholar
• Trivedi P, Wang S, Friedman SL. The power of Plasticity-Metabolic regulation of hepatic stellate cells. Cell Metab. 2021;33(2):242–257.
   PubMed Web of Science ®Google Scholar
• Zheng D, Jiang Y, Qu C, et al. Pyruvate kinase M2 tetramerization protects against hepatic stellate cell activation and liver fibrosis. Am J Pathol. 2020;190(11):2267–2281.
   PubMed Web of Science ®Google Scholar
• Liu J, Jiang S, Zhao Y, et al. Geranylgeranyl diphosphate synthase (GGPPS) regulates non-alcoholic fatty liver disease (NAFLD)-fibrosis progression by determining hepatic glucose/fatty acid preference under high-fat diet conditions. J Pathol. 2018;246(3):277–288.
   PubMed Web of Science ®Google Scholar
• Yang L, Roh YS, Song J, et al. Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology. 2014;59(2):483–495.
   PubMed Web of Science ®Google Scholar
• Zhang J, Muise ES, Han S, et al. Molecular profiling reveals a common metabolic signature of tissue fibrosis. Cell Rep Med. 2020;1(4):100056.
   PubMedGoogle Scholar
• Kuchay MS, Choudhary NS, Mishra SK. Pathophysiological mechanisms underlying MAFLD. Diabetes Metab Syndr. 2020;14(6):1875–1887.
   PubMed Web of Science ®Google Scholar
• Bobowski-Gerard M, Zummo FP, Staels B, et al. Retinoids issued from hepatic stellate cell lipid droplet loss as potential signaling molecules orchestrating a multicellular liver injury response. Cells. 2018;7(9):137.
   PubMed Web of Science ®Google Scholar
• Hernández-Gea V, Ghiassi-Nejad Z, Rozenfeld R, et al. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology. 2012;142(4):938–946.
   PubMed Web of Science ®Google Scholar
• Ye P, Xiang M, Liao H, et al. Dual-specificity phosphatase 9 protects against nonalcoholic fatty liver disease in mice through ASK1 suppression. Hepatology. 2019;69(1):76–93.
   PubMed Web of Science ®Google Scholar
• Fang W, Deng Z, Benadjaoud F, et al. Cathepsin B deficiency ameliorates liver lipid deposition, inflammatory cell infiltration, and fibrosis after diet-induced nonalcoholic steatohepatitis. Transl Res. 2020;222:28–40.
   PubMed Web of Science ®Google Scholar
• Gluais-Dagorn P, Foretz M, Steinberg GR, et al. Direct AMPK activation corrects NASH in rodents through metabolic effects and direct action on inflammation and fibrogenesis. Hepatol Commun. 2022;6(1):101–119.
   PubMed Web of Science ®Google Scholar
• Hu J, Du H, Yuan Y, et al. MFG-E8 knockout aggravated nonalcoholic steatohepatitis by promoting the activation of TLR4/NF-κB signaling in mice. Mediators Inflamm. 2022;2022:5791915.
   PubMed Web of Science ®Google Scholar
• Aragón-Herrera A, Otero-Santiago M, Anido-Varela L, et al. The treatment with the SGLT2 inhibitor empagliflozin modifies the hepatic metabolome of male zucker diabetic fatty rats towards a protective profile. Front Pharmacol. 2022;13:827033.
   PubMed Web of Science ®Google Scholar
• Wu KT, Kuo PL, Su SB, et al. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. J Clin Lipidol. 2016;10(2):420–425.e1.
   PubMed Web of Science ®Google Scholar
• Wang G, Li Z, Li H, et al. Metabolic profile changes of CCl4-Liver fibrosis and inhibitory effects of Jiaqi Ganxian granule. Molecules. 2016;21(6):698.
   PubMed Web of Science ®Google Scholar
• Liu Y, Binz J, Numerick MJ, et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest. 2003;112(11):1678–1687.
   PubMed Web of Science ®Google Scholar
• Li J, Kuruba R, Wilson A, et al. Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand. PLoS One. 2010;5(11):e13955.
   PubMed Web of Science ®Google Scholar
• Yan T, Luo Y, Yan N, et al. Intestinal peroxisome proliferator-activated receptor α-fatty acid-binding protein 1 axis modulates nonalcoholic steatohepatitis. Hepatology. 2022;2022:hep.32538.
   Google Scholar
• Samah M, El-Aidy Ael R, Tawfik MK, et al. Evaluation of the antifibrotic effect of fenofibrate and rosiglitazone on bleomycin-induced pulmonary fibrosis in rats. Eur J Pharmacol. 2012;689(1–3):186–193.
   PubMed Web of Science ®Google Scholar
• Oruqaj G, Karnati S, Vijayan V, et al. Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-β signaling. Proc Natl Acad Sci USA. 2015;112(16):E2048–57.
   PubMed Web of Science ®Google Scholar
• Kim K, Bae GD, Lee M, et al. Allomyrina dichotoma larva extract ameliorates the hepatic insulin resistance of high-fat diet-induced diabetic mice. Nutrients. 2019;11(7):1522.
   PubMed Web of Science ®Google Scholar
• Yu M, Zhu Y, Cong Q, et al. Metabonomics research progress on liver diseases. Can J Gastroenterol Hepatol. 2017;2017:8467192.
   PubMed Web of Science ®Google Scholar
• Enomoto H, Sakai Y, Aizawa N, et al. Association of amino acid imbalance with the severity of liver fibrosis and esophageal varices. Ann Hepatol. 2013;12(3):471–478.
   PubMed Web of Science ®Google Scholar
• Gaggini M, Carli F, Rosso C, et al. Altered amino acid concentrations in NAFLD: impact of obesity and insulin resistance. Hepatology. 2018;67(1):145–158.
   PubMed Web of Science ®Google Scholar
• Du K, Hyun J, Premont RT, et al. Hedgehog-YAP signaling pathway regulates glutaminolysis to control activation of hepatic stellate cells. Gastroenterology. 2018;154(5):1465–1479.e13.
   PubMed Web of Science ®Google Scholar
• Li J, Ghazwani M, Liu K, et al. Regulation of hepatic stellate cell proliferation and activation by glutamine metabolism. PLoS One. 2017;12(8):e0182679.
   PubMed Web of Science ®Google Scholar
• Huang T, Terrell JA, Chung JH, et al. Electrospun microfibers modulate intracellular amino acids in liver cells via integrin β1. Bioengineering. 2021;8(7):88.
   PubMedGoogle Scholar
• Chakravarthy MV, Neutel J, Confer S, et al. Safety, tolerability, and physiological effects of AXA1665, a novel composition of amino acids, in subjects with child-Pugh a and B cirrhosis. Clin Transl Gastroenterol. 2020;11(8):e00222.
   PubMedGoogle Scholar
• Holeček M. Branched-Chain amino acids and branched-chain Keto acids in hyperammonemic states: metabolism and as supplements. Metabolites. 2020;10(8):324.
   PubMed Web of Science ®Google Scholar
• Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev. 2014;94(3):909–950.
   PubMed Web of Science ®Google Scholar
• Krähenbühl S, Krähenbühl-Glauser S, Stucki J, et al. Stereological and functional analysis of liver mitochondria from rats with secondary biliary cirrhosis: impaired mitochondrial metabolism and increased mitochondrial content per hepatocyte. Hepatology. 1992;15(6):1167–1172.
   PubMed Web of Science ®Google Scholar
• Di Ciaula A, Passarella S, Shanmugam H, et al. Nonalcoholic Fatty Liver Disease (NAFLD). mitochondria as players and targets of therapies? Int J Mol Sci. 2021;22(10):5375.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang Z, Feng D, et al. p66Shc contributes to liver fibrosis through the regulation of mitochondrial reactive oxygen species. Theranostics. 2019;9(5):1510–1522.
   PubMed Web of Science ®Google Scholar
• Low TY, Leow CK, Salto-Tellez M, et al. A proteomic analysis of thioacetamide-induced hepatotoxicity and cirrhosis in rat livers. Proteomics. 2004;4(12):3960–3974.
   PubMed Web of Science ®Google Scholar
• Diamond DL, Jacobs JM, Paeper B, et al. Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction. Hepatology. 2007;46(3):649–657.
   PubMed Web of Science ®Google Scholar
• Li Z, Li Y, Zhang HX, et al. Mitochondria-mediated pathogenesis and therapeutics for non-alcoholic fatty liver disease. Mol Nutr Food Res. 2019;63(16):e1900043.
   PubMed Web of Science ®Google Scholar
• Durand M, Coué M, Croyal M, et al. Changes in key mitochondrial lipids accompany mitochondrial dysfunction and oxidative stress in NAFLD. Oxid Med Cell Longev. 2021;2021:9986299.
   PubMed Web of Science ®Google Scholar
• Fernández-Tussy P, Fernández-Ramos D, Lopitz-Otsoa F, et al. miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease. Mol Metab. 2019;29:40–54.
   PubMed Web of Science ®Google Scholar
• Chella Krishnan K, Floyd RR, Sabir S, et al. Liver pyruvate kinase promotes NAFLD/NASH in both mice and humans in a Sex-Specific manner. Cell Mol Gastroenterol Hepatol. 2021;11(2):389–406.
   PubMed Web of Science ®Google Scholar
• Pusec CM, De Jesus A, Khan MW, et al. Hepatic HKDC1 expression contributes to liver metabolism. Endocrinology. 2019;160(2):313–330.
   PubMed Web of Science ®Google Scholar
• Kubes P, Jenne C. Immune responses in the liver. Annu Rev Immunol. 2018;36:247–277.
   PubMed Web of Science ®Google Scholar
• Liaskou E, Wilson DV, Oo YH. Innate immune cells in liver inflammation. Mediators Inflamm. 2012;2012:949157.
   PubMed Web of Science ®Google Scholar
• O’Rourke JM, Sagar VM, Shah T, et al. Carcinogenesis on the background of liver fibrosis: implications for the management of hepatocellular cancer. World J Gastroenterol. 2018;24(39):4436–4447.
   PubMed Web of Science ®Google Scholar
• Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol. 2017;17(5):306–321.
   PubMed Web of Science ®Google Scholar
• Aydın MM, Akçalı KC. Liver fibrosis. Turk J Gastroenterol. 2018;29(1):14–21.
   PubMed Web of Science ®Google Scholar
• Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9(4):875.
   PubMed Web of Science ®Google Scholar
• Seki E, Schwabe RF. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology. 2015;61(3):1066–1079.
   PubMed Web of Science ®Google Scholar
• Shi J, Zhao J, Zhang X, et al. Activated hepatic stellate cells impair NK cell anti-fibrosis capacity through a TGF-β-dependent emperipolesis in HBV cirrhotic patients. Sci Rep. 2017;7:44544.
   PubMed Web of Science ®Google Scholar
• Jeong WI, Gao B. Innate immunity and alcoholic liver fibrosis. J Gastroenterol Hepatol. 2008;23(Suppl 1):S112–S8.
   PubMedGoogle Scholar
• Jeong WI, Park O, Suh YG, et al. Suppression of innate immunity (natural killer cell/interferon-γ) in the advanced stages of liver fibrosis in mice. Hepatology. 2011;53(4):1342–1351.
   PubMed Web of Science ®Google Scholar
• Gao B, Radaeva S. Natural killer and natural killer T cells in liver fibrosis. Biochim Biophys Acta. 2013;1832(7):1061–1069.
   PubMed Web of Science ®Google Scholar
• Hammoutene A, Rautou PE. Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease. J Hepatol. 2019;70(6):1278–1291.
   PubMed Web of Science ®Google Scholar
• Kumar S, Duan Q, Wu R, et al. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis. Adv Drug Deliv Rev. 2021;176:113869.
   PubMed Web of Science ®Google Scholar
• Matsuda M, Seki E. The liver fibrosis niche: Novel insights into the interplay between fibrosis-composing mesenchymal cells, immune cells, endothelial cells, and extracellular matrix. Food Chem Toxicol. 2020;143:111556.
   PubMed Web of Science ®Google Scholar
• Chen RJ, Wu HH, Wang YJ. Strategies to prevent and reverse liver fibrosis in humans and laboratory animals. Arch Toxicol. 2015;89(10):1727–1750.
   PubMed Web of Science ®Google Scholar
• Mack M. Inflammation and fibrosis. Matrix Biol. 2018;68–69:106–121.
   PubMed Web of Science ®Google Scholar
• McAnulty RJ. Fibroblasts and myofibroblasts: their source, function and role in disease. Int J Biochem Cell Biol. 2007;39(4):666–671.
   PubMed Web of Science ®Google Scholar
• Stone RC, Pastar I, Ojeh N, et al. Epithelial-mesenchymal transition in tissue repair and fibrosis. Cell Tissue Res. 2016;365(3):495–506.
   PubMed Web of Science ®Google Scholar
• Lua I, Li Y, Zagory JA, et al. Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers. J Hepatol. 2016;64(5):1137–1146.
   PubMed Web of Science ®Google Scholar
• Iwaisako K, Jiang C, Zhang M, et al. Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci USA. 2014;111(32):E3297–305.
   PubMed Web of Science ®Google Scholar
• Mederacke I, Hsu CC, Troeger JS, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013;4:2823.
   PubMed Web of Science ®Google Scholar
• Kisseleva T, Uchinami H, Feirt N, et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol. 2006;45(3):429–438.
   PubMed Web of Science ®Google Scholar
• Pellicoro A, Ramachandran P, Iredale JP, et al. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014;14(3):181–194.
   PubMed Web of Science ®Google Scholar
• Tanwar S, Rhodes F, Srivastava A, et al. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. World J Gastroenterol. 2020;26(2):109–133.
   PubMed Web of Science ®Google Scholar
• Godwin JW, Pinto AR, Rosenthal NA. Chasing the recipe for a pro-regenerative immune system. Semin Cell Dev Biol. 2017;61:71–79.
   PubMedGoogle Scholar
• Elsherif SA, Alm AS. Role of macrophages in liver cirrhosis: fibrogenesis and resolution. Anat Cell Biol. 2022;55(1):14–19.
   PubMed Web of Science ®Google Scholar
• Fallowfield JA, Mizuno M, Kendall TJ, et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol. 2007;178(8):5288–5295.
   PubMed Web of Science ®Google Scholar
• Nilsson J, Hörnberg M, Schmidt-Christensen A, et al. NKT cells promote both type 1 and type 2 inflammatory responses in a mouse model of liver fibrosis. Sci Rep. 2020;10(1):21778.
   PubMed Web of Science ®Google Scholar
• Wang H, Yin S. Natural killer T cells in liver injury, inflammation and cancer. Expert Rev Gastroenterol Hepatol. 2015;9(8):1077–1085.
   PubMed Web of Science ®Google Scholar
• Mitra A, Satelli A, Yan J, et al. IL-30 (IL27p28) attenuates liver fibrosis through inducing NKG2D-rae1 interaction between NKT and activated hepatic stellate cells in mice. Hepatology. 2014;60(6):2027–2039.
   PubMed Web of Science ®Google Scholar
• Poisson J, Lemoinne S, Boulanger C, et al. Liver sinusoidal endothelial cells: physiology and role in liver diseases. J Hepatol. 2017;66(1):212–227.
   PubMed Web of Science ®Google Scholar
• Lafoz E, Ruart M, Anton A, et al. The endothelium as a driver of liver fibrosis and regeneration. Cells. 2020;9(4):929.
   PubMed Web of Science ®Google Scholar
• Iwakiri Y, Shah V, Rockey DC. Vascular pathobiology in chronic liver disease and cirrhosis – current status and future directions. J Hepatol. 2014;61(4):912–924.
   PubMed Web of Science ®Google Scholar
• Pi X, Xie L, Patterson C. Emerging roles of vascular endothelium in metabolic homeostasis. Circ Res. 2018;123(4):477–494.
   PubMed Web of Science ®Google Scholar
• Elvevold K, Smedsrød B, Martinez I. The liver sinusoidal endothelial cell: a cell type of controversial and confusing identity. Am J Physiol Gastrointest Liver Physiol. 2008;294(2):G391–400.
   PubMed Web of Science ®Google Scholar
• Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol. 2002;1(1):1.
   PubMedGoogle Scholar
• DeLeve LD. Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatology. 2015;61(5):1740–1746.
   PubMed Web of Science ®Google Scholar
• Huang C, Ogawa R. The vascular involvement in soft tissue Fibrosis-lessons learned from pathological scarring. Int J Mol Sci. 2020;21(7):2542.
   PubMed Web of Science ®Google Scholar
• Deleve LD, Wang X, Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology. 2008;48(3):920–930.
   PubMed Web of Science ®Google Scholar
• Gupta TK, Toruner M, Chung MK, et al. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology. 1998;28(4):926–931.
   PubMed Web of Science ®Google Scholar
• Matei V, Rodríguez-Vilarrupla A, Deulofeu R, et al. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology. 2006;44(1):44–52.
   PubMed Web of Science ®Google Scholar
• Fleischer JR, Jodszuweit CA, Ghadimi M, et al. Vascular heterogeneity with a special focus on the hepatic microenvironment. Front Physiol. 2020;11(591901):591901.
   PubMedGoogle Scholar
• Brusilovskaya K, Königshofer P, Schwabl P, et al. Vascular targets for the treatment of portal hypertension. Semin Liver Dis. 2019;39(4):483–501.
   PubMed Web of Science ®Google Scholar
• Povero D, Panera N, Eguchi A, et al. Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-γ. Cell Mol Gastroenterol Hepatol. 2015;1(6):646–663.e4.
   PubMed Web of Science ®Google Scholar
• Tugues S, Fernandez-Varo G, Muñoz-Luque J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology. 2007;46(6):1919–1926.
   PubMed Web of Science ®Google Scholar
• Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol. 2010;7(8):425–436.
   PubMed Web of Science ®Google Scholar
• Ding BS, Cao Z, Lis R, et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature. 2014;505(7481):97–102.
   PubMed Web of Science ®Google Scholar
• Fernández M, Semela D, Bruix J, et al. Angiogenesis in liver disease. J Hepatol. 2009;50(3):604–620.
   PubMed Web of Science ®Google Scholar
• Ogawa R, Akaishi S. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis – Keloids and hypertrophic scars may be vascular disorders. Med Hypotheses. 2016;96:51–60.
   PubMed Web of Science ®Google Scholar
• Taura K, De Minicis S, Seki E, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology. 2008;135(5):1729–1738.
   PubMed Web of Science ®Google Scholar
• Cong M, Liu T, Wang P, et al. Antifibrotic effects of a recombinant adeno-associated virus carrying small interfering RNA targeting TIMP-1 in rat liver fibrosis. Am J Pathol. 2013;182(5):1607–1616.
   PubMed Web of Science ®Google Scholar
• Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem. 2003;88(4):660–672.
   PubMed Web of Science ®Google Scholar
• Georges PC, Hui JJ, Gombos Z, et al. Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol. 2007;293(6):G1147–54.
   PubMed Web of Science ®Google Scholar
• Perepelyuk M, Terajima M, Wang AY, et al. Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury. Am J Physiol Gastrointest Liver Physiol. 2013;304(6):G605–14.
   PubMed Web of Science ®Google Scholar
• Liu SB, Ikenaga N, Peng ZW, et al. Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice. Faseb J. 2016;30(4):1599–1609.
   PubMed Web of Science ®Google Scholar
• Ikenaga N, Peng ZW, Vaid KA, et al. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. Gut. 2017;66(9):1697–1708.
   PubMed Web of Science ®Google Scholar
• Chen G, Xia B, Fu Q, et al. Matrix mechanics as regulatory factors and therapeutic targets in hepatic fibrosis. Int J Biol Sci. 2019;15(12):2509–2521.
   PubMed Web of Science ®Google Scholar
• Iredale JP, Thompson A, Henderson NC. Extracellular matrix degradation in liver fibrosis: biochemistry and regulation. Biochim Biophys Acta. 2013;1832(7):876–883.
   PubMed Web of Science ®Google Scholar
• Massey VL, Dolin CE, Poole LG, et al. The hepatic "matrisome" responds dynamically to injury: characterization of transitional changes to the extracellular matrix in mice. Hepatology. 2017;65(3):969–982.
   PubMed Web of Science ®Google Scholar
• Akbari Dilmaghnai N, Shoorei H, Sharifi G, et al. Non-coding RNAs modulate function of extracellular matrix proteins. Biomed Pharmacother. 2021;136:111240.
   PubMed Web of Science ®Google Scholar
• Popov Y, Patsenker E, Stickel F, et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol. 2008;48(3):453–464.
   PubMed Web of Science ®Google Scholar
• Conroy KP, Kitto LJ, Henderson NC. αv integrins: key regulators of tissue fibrosis. Cell Tissue Res. 2016;365(3):511–519.
   PubMed Web of Science ®Google Scholar
• Song S, Shackel NA, Wang XM, et al. Discoidin domain receptor 1: isoform expression and potential functions in cirrhotic human liver. Am J Pathol. 2011;178(3):1134–1144.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Manon-Jensen T, Genovese F, et al. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2015;308(10):G807–30.
   PubMed Web of Science ®Google Scholar
• Schuppan D, Schmid M, Somasundaram R, et al. Collagens in the liver extracellular matrix bind hepatocyte growth factor. Gastroenterology. 1998;114(1):139–152.
   PubMed Web of Science ®Google Scholar
• Natarajan V, Harris EN, Kidambi S. SECs (sinusoidal endothelial cells), liver microenvironment, and fibrosis. Biomed Res Int. 2017;2017:4097205.
   PubMed Web of Science ®Google Scholar
• Caliari SR, Perepelyuk M, Soulas EM, et al. Gradually softening hydrogels for modeling hepatic stellate cell behavior during fibrosis regression. Integr Biol. 2016;8(6):720–728.
   Google Scholar
• Olsen AL, Bloomer SA, Chan EP, et al. Hepatic stellate cells require a stiff environment for myofibroblastic differentiation. Am J Physiol Gastrointest Liver Physiol. 2011;301(1):G110–8.
   PubMed Web of Science ®Google Scholar
• Liu L, You Z, Yu H, et al. Mechanotransduction-modulated fibrotic microniches reveal the contribution of angiogenesis in liver fibrosis. Nat Mater. 2017;16(12):1252–1261.
   PubMed Web of Science ®Google Scholar
• El-Safy S, Tammam SN, Abdel-Halim M, et al. Collagenase loaded chitosan nanoparticles for digestion of the collagenous scar in liver fibrosis: the effect of chitosan intrinsic collagen binding on the success of targeting. Eur J Pharm Biopharm. 2020;148:54–66.
   PubMed Web of Science ®Google Scholar
• Thomas JA, Pope C, Wojtacha D, et al. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function. Hepatology. 2011;53(6):2003–2015.
   PubMed Web of Science ®Google Scholar
• Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16(9):1009–1017.
   PubMed Web of Science ®Google Scholar
• Mannaerts I, Leite SB, Verhulst S, et al. The Hippo pathway effector Yap controls mouse hepatic stellate cell activation. J Hepatol. 2015;63(3):679–688.
   PubMed Web of Science ®Google Scholar
• Murata T, Arii S, Nakamura T, et al. Inhibitory effect of Y-27632, a ROCK inhibitor, on progression of rat liver fibrosis in association with inactivation of hepatic stellate cells. J Hepatol. 2001;35(4):474–481.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468–475.
   PubMed Web of Science ®Google Scholar
• Ebrahimi H, Naderian M, Sohrabpour AA. New concepts on reversibility and targeting of liver fibrosis; a review article. Middle East J Dig Dis. 2018;10(3):133–148.
   PubMedGoogle Scholar
• Glass LM, Dickson RC, Anderson JC, et al. Total body weight loss of ≥ 10% is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2015;60(4):1024–1030.
   PubMed Web of Science ®Google Scholar
• Sun YM, Chen SY, You H. Regression of liver fibrosis: evidence and challenges. Chin Med J. 2020;133(14):1696–1702.
   PubMed Web of Science ®Google Scholar
• Abu Dayyeh BK, Yang M, Dienstag JL, et al. The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C trial cohort. Dig Dis Sci. 2011;56(2):564–568.
   PubMed Web of Science ®Google Scholar
• McHutchison J, Goodman Z, Patel K, et al. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology. 2010;138(4):1365–1373.
   PubMed Web of Science ®Google Scholar
• Liu L, Yannam GR, Nishikawa T, et al. The microenvironment in hepatocyte regeneration and function in rats with advanced cirrhosis. Hepatology. 2012;55(5):1529–1539.
   PubMed Web of Science ®Google Scholar
• Kisseleva T, Cong M, Paik Y, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci USA. 2012;109(24):9448–9453.
   PubMed Web of Science ®Google Scholar
• Troeger JS, Mederacke I, Gwak GY, et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology. 2012;143(4):1073–1083.e22.
   PubMed Web of Science ®Google Scholar